M
Maciej J. Zamek-Gliszczynski
Researcher at GlaxoSmithKline
Publications - 70
Citations - 6568
Maciej J. Zamek-Gliszczynski is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Pharmacokinetics & Excretion. The author has an hindex of 36, co-authored 65 publications receiving 5722 citations. Previous affiliations of Maciej J. Zamek-Gliszczynski include Eli Lilly and Company & Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Membrane transporters in drug development.
Kathleen M. Giacomini,Shiew-Mei Huang,Donald J. Tweedie,Leslie Z. Benet,Kim L. R. Brouwer,Xiaoyan Chu,Amber Dahlin,Raymond Evers,Volker Fischer,Kathleen M. Hillgren,Keith Hoffmaster,Toshihisa Ishikawa,Dietrich Keppler,Richard B. Kim,Caroline A. Lee,Mikko Niemi,Joseph W. Polli,Yuicchi Sugiyama,Peter W. Swaan,Joseph A. Ware,Stephen H. Wright,Sook Wah Yee,Maciej J. Zamek-Gliszczynski,Lei Zhang +23 more
TL;DR: Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions, as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Journal ArticleDOI
Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites
Maciej J. Zamek-Gliszczynski,Keith Hoffmaster,Ken Ichi Nezasa,Melanie N. Tallman,Kim L. R. Brouwer +4 more
TL;DR: This review summarizes sulfation, glucuronidation, and glutathione conjugation reactions, as well as recent progress in elucidating the hepatic transport mechanisms responsible for the excretion of these conjugates from the liver, and focuses on alterations of metabolism and transport by chemical modulators, and disease states.
Journal ArticleDOI
Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
J C Kalvass,Joseph W. Polli,DL Bourdet,Bo Feng,Huang Sm,X Liu,Quentin R. Smith,Lei Zhang,Maciej J. Zamek-Gliszczynski +8 more
TL;DR: Evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.
Journal ArticleDOI
Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance
Maciej J. Zamek-Gliszczynski,Mitchell E. Taub,Paresh P. Chothe,Xiaoyan Chu,Kathleen M. Giacomini,Richard B. Kim,Adrian S. Ray,Sophie L. Stocker,Jashvant D. Unadkat,Matthias B. Wittwer,Cindy Q. Xia,Sook Wah Yee,Lei Zhang,Yan Zhang +13 more
TL;DR: For the first time, the ITC underscores the importance of transporters involved in drug‐induced vitamin deficiency (THTR2) and those involved in the disposition of biomarkers of organ function (OAT2 and bile acidtransporters).
Journal ArticleDOI
Pharmacokinetics of 5 (and 6)-Carboxy-2′,7′-Dichlorofluorescein and Its Diacetate Promoiety in the Liver
Maciej J. Zamek-Gliszczynski,Hao Xiong,Nita J. Patel,Ryan Z. Turncliff,Gary M. Pollack,Kim L. R. Brouwer +5 more
TL;DR: Hepatic disposition of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein and its diacetate promoiety was studied in isolated perfused rat livers and appeared to be taken up by Oatp-mediated transport into rat hepatocytes and effluxed via Mrp2 into bile and viaMrp3 into sinusoidal blood.